Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prevent from home cardiovascular health improvement feasibility study
ISRCTN17524311Phase 2Recruiting
- Sponsor
- King's College London
- Start
- Mar 2025
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Peptides
01
Overview
Phase 2, randomised, open-label trial in maternal hypertension (HDP) and gestational diabetes mellitus (GDM) comparing dapagliflozin with tirzepatide (2 arms). Primary endpoint: Overall recruitment rate of postpartum participants. Started Mar 2025; status: recruiting.
02
Drugs
dapagliflozintirzepatide
03
Conditions
maternal hypertension (HDP)gestational diabetes mellitus (GDM)
Beyond the preview
Go deeper on ISRCTN17524311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN17524311.